BRNS
Barinthus Biotherapeutics plc
NASDAQ · Healthcare · Biotechnology · GB
$0.76
+5.50%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +40.0%
- EBIT
- +41.8%
- EPS
- +40.5%
- Free cash flow
- +31.5%
- Operating cash flow
- +30.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +51.3%
- EPS
- -5.3%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -13.6%
- EBIT
- +20.3%
- Net income
- -9.0%
- EPS
- -5.8%
- Free cash flow
- -61.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026